Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026)
Cogent Biosciences' (COGT) quarterly Return on Capital Employed came in at 41.98% in Q1 2026, up 7047.0% year-on-year from 0.59% in Q1 2025, and up 22.19% on a QoQ basis from 53.96% in Q4 2025.
Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has 9 years of Return on Capital Employed data on file, last reported at 41.98% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 7047.0% year-over-year to 41.98% in Q1 2026; TTM through Mar 2026 was 41.98%, a 7047.0% increase from a year earlier, with the FY2025 full-year figure at 58.61%, up 4554.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 41.98%, up from 53.96% in the prior quarter.
- Over the last five years, Return on Capital Employed for COGT reached as high as 39.89% in Q3 2022 and fell as low as 135.66% in Q2 2025.
- Historically, Return on Capital Employed has averaged 68.55% across 5 years, with a median of 59.22% in 2024.
- Across the five-year window, Return on Capital Employed sank 7644 bps in 2025 and jumped 7047 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 51.1% in 2022, then plunged by 37 bps to 70.25% in 2023, then tumbled by 31 bps to 91.9% in 2024, then soared by 41 bps to 53.96% in 2025, then increased by 22 bps to 41.98% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 41.98% in Q1 2026, 53.96% in Q4 2025, and 106.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Cogent Biosciences | 6.45 Bn | 6.45 Bn | - | -41.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.98% |
| Dec 31, 2025 | -53.96% |
| Sep 30, 2025 | -106.76% |
| Jun 30, 2025 | -135.66% |
| Mar 31, 2025 | -112.45% |
| Dec 31, 2024 | -91.90% |
| Sep 30, 2024 | -73.58% |
| Jun 30, 2024 | -59.22% |
| Mar 31, 2024 | -63.48% |
| Dec 31, 2023 | -70.25% |
| Sep 30, 2023 | -57.09% |
| Jun 30, 2023 | -56.58% |
| Mar 31, 2023 | -61.20% |
| Dec 31, 2022 | -51.10% |
| Sep 30, 2022 | -39.89% |
| Jun 30, 2022 | -43.56% |
| Mar 31, 2022 | -46.71% |
| Dec 31, 2021 | -36.56% |
| Sep 30, 2021 | -29.90% |
| Jun 30, 2021 | -45.01% |